October 14, 2011
Bainbridge Island, WA. October 14, 2011. Pieris AG (Freising, Germany ) has selected Emerald BioStructures, Inc. to resolve the three dimensional structures of bioengineered Anticalin® proteins in complex with target antigen proteins. The structural studies will support Pieris’ efforts to confirm details of Anticalin-antigen interactions and utilize the information for structure guided design of next generation protein therapeutics. This fee based and milestone project will utilize Emerald’s high throughput crystallization platform and biophysical tool set for characterization of protein-protein and antigen-antibody interactions.
About Emerald BioStructures
Emerald BioStructures is an integrated gene-to-structure contract research organization that provides collaborative drug discovery services to pharmaceutical companies, biotechnology companies, academic institutions, and government facilities. The company operates a high-throughput platform leveraged for fragment-based lead discovery, structure-based drug design, and elucidation of antibody-antigen structures. Emerald’s work provides a solid foundation for the discovery of highly selective, efficacious drugs. www.emeraldbiostructures.com
About Pieris AG
Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create safer, more efficacious and more convenient protein therapeutics. Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches. Pieris’ pipeline ranges from its Phase I compound, PRS-050 (anti-VEGF, oncology), to multiple Anticalins in preclinical development. The company has four ongoing discovery and development collaborations: Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan. Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures. For more information, please visit: www.pieris-ag.com.
Emerald BioStructures Contact:
Emerald BioStructures: Diana Wetmore, VP of Business Development & Alliances (206) 780-8959, firstname.lastname@example.org
Pieris AG Contact:
Pieris AG: Laurent Audoly PhD, CSO and Head of Research & Development, Audoly@pieris-ag.com